Browse IL6

Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00489 Interleukin-6/G-CSF/MGF family
Function

Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation.

> Gene Ontology
 
Biological Process GO:0000060 protein import into nucleus, translocation
GO:0000302 response to reactive oxygen species
GO:0001101 response to acid chemical
GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001562 response to protozoan
GO:0001649 osteoblast differentiation
GO:0001763 morphogenesis of a branching structure
GO:0001776 leukocyte homeostasis
GO:0001780 neutrophil homeostasis
GO:0001781 neutrophil apoptotic process
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001878 response to yeast
GO:0001894 tissue homeostasis
GO:0001933 negative regulation of protein phosphorylation
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002251 organ or tissue specific immune response
GO:0002262 myeloid cell homeostasis
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002295 T-helper cell lineage commitment
GO:0002360 T cell lineage commitment
GO:0002363 alpha-beta T cell lineage commitment
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002369 T cell cytokine production
GO:0002377 immunoglobulin production
GO:0002384 hepatic immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002526 acute inflammatory response
GO:0002548 monocyte chemotaxis
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002673 regulation of acute inflammatory response
GO:0002675 positive regulation of acute inflammatory response
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002711 positive regulation of T cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0002724 regulation of T cell cytokine production
GO:0002726 positive regulation of T cell cytokine production
GO:0002790 peptide secretion
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002828 regulation of type 2 immune response
GO:0002830 positive regulation of type 2 immune response
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006094 gluconeogenesis
GO:0006109 regulation of carbohydrate metabolic process
GO:0006111 regulation of gluconeogenesis
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006417 regulation of translation
GO:0006469 negative regulation of protein kinase activity
GO:0006606 protein import into nucleus
GO:0006809 nitric oxide biosynthetic process
GO:0006913 nucleocytoplasmic transport
GO:0006925 inflammatory cell apoptotic process
GO:0006953 acute-phase response
GO:0006959 humoral immune response
GO:0006979 response to oxidative stress
GO:0007159 leukocyte cell-cell adhesion
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0007262 STAT protein import into nucleus
GO:0007431 salivary gland development
GO:0007435 salivary gland morphogenesis
GO:0007517 muscle organ development
GO:0007568 aging
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0007622 rhythmic behavior
GO:0007623 circadian rhythm
GO:0008360 regulation of cell shape
GO:0009266 response to temperature stimulus
GO:0009306 protein secretion
GO:0009408 response to heat
GO:0009409 response to cold
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0009620 response to fungus
GO:0009914 hormone transport
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010466 negative regulation of peptidase activity
GO:0010573 vascular endothelial growth factor production
GO:0010574 regulation of vascular endothelial growth factor production
GO:0010608 posttranscriptional regulation of gene expression
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010677 negative regulation of cellular carbohydrate metabolic process
GO:0010712 regulation of collagen metabolic process
GO:0010713 negative regulation of collagen metabolic process
GO:0010720 positive regulation of cell development
GO:0010817 regulation of hormone levels
GO:0010876 lipid localization
GO:0010883 regulation of lipid storage
GO:0010888 negative regulation of lipid storage
GO:0010906 regulation of glucose metabolic process
GO:0010951 negative regulation of endopeptidase activity
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0010996 response to auditory stimulus
GO:0014074 response to purine-containing compound
GO:0015833 peptide transport
GO:0016049 cell growth
GO:0016051 carbohydrate biosynthetic process
GO:0017038 protein import
GO:0018105 peptidyl-serine phosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018212 peptidyl-tyrosine modification
GO:0019226 transmission of nerve impulse
GO:0019318 hexose metabolic process
GO:0019319 hexose biosynthetic process
GO:0019915 lipid storage
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022410 circadian sleep/wake cycle process
GO:0022604 regulation of cell morphogenesis
GO:0022612 gland morphogenesis
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030098 lymphocyte differentiation
GO:0030168 platelet activation
GO:0030217 T cell differentiation
GO:0030278 regulation of ossification
GO:0030335 positive regulation of cell migration
GO:0030431 sleep
GO:0030595 leukocyte chemotaxis
GO:0031000 response to caffeine
GO:0031016 pancreas development
GO:0031018 endocrine pancreas development
GO:0031346 positive regulation of cell projection organization
GO:0031349 positive regulation of defense response
GO:0031644 regulation of neurological system process
GO:0031646 positive regulation of neurological system process
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031960 response to corticosteroid
GO:0032103 positive regulation of response to external stimulus
GO:0032355 response to estradiol
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032494 response to peptidoglycan
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032635 interleukin-6 production
GO:0032642 regulation of chemokine production
GO:0032675 regulation of interleukin-6 production
GO:0032682 negative regulation of chemokine production
GO:0032722 positive regulation of chemokine production
GO:0032755 positive regulation of interleukin-6 production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032868 response to insulin
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0032963 collagen metabolic process
GO:0032964 collagen biosynthetic process
GO:0032965 regulation of collagen biosynthetic process
GO:0032966 negative regulation of collagen biosynthetic process
GO:0033002 muscle cell proliferation
GO:0033028 myeloid cell apoptotic process
GO:0033135 regulation of peptidyl-serine phosphorylation
GO:0033138 positive regulation of peptidyl-serine phosphorylation
GO:0033157 regulation of intracellular protein transport
GO:0033158 regulation of protein import into nucleus, translocation
GO:0033160 positive regulation of protein import into nucleus, translocation
GO:0033500 carbohydrate homeostasis
GO:0033673 negative regulation of kinase activity
GO:0034103 regulation of tissue remodeling
GO:0034104 negative regulation of tissue remodeling
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0034504 protein localization to nucleus
GO:0034599 cellular response to oxidative stress
GO:0034612 response to tumor necrosis factor
GO:0034614 cellular response to reactive oxygen species
GO:0035270 endocrine system development
GO:0035272 exocrine system development
GO:0035637 multicellular organismal signaling
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035728 response to hepatocyte growth factor
GO:0035729 cellular response to hepatocyte growth factor stimulus
GO:0035743 CD4-positive, alpha-beta T cell cytokine production
GO:0035745 T-helper 2 cell cytokine production
GO:0040017 positive regulation of locomotion
GO:0042033 chemokine biosynthetic process
GO:0042035 regulation of cytokine biosynthetic process
GO:0042036 negative regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0042326 negative regulation of phosphorylation
GO:0042391 regulation of membrane potential
GO:0042493 response to drug
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042542 response to hydrogen peroxide
GO:0042593 glucose homeostasis
GO:0042742 defense response to bacterium
GO:0042745 circadian sleep/wake cycle
GO:0042748 circadian sleep/wake cycle, non-REM sleep
GO:0042749 regulation of circadian sleep/wake cycle
GO:0042752 regulation of circadian rhythm
GO:0042832 defense response to protozoan
GO:0042886 amide transport
GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043200 response to amino acid
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043279 response to alkaloid
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043368 positive T cell selection
GO:0043369 CD4-positive or CD8-positive, alpha-beta T cell lineage commitment
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043373 CD4-positive, alpha-beta T cell lineage commitment
GO:0043410 positive regulation of MAPK cascade
GO:0043434 response to peptide hormone
GO:0043491 protein kinase B signaling
GO:0044057 regulation of system process
GO:0044236 multicellular organism metabolic process
GO:0044246 regulation of multicellular organismal metabolic process
GO:0044252 negative regulation of multicellular organismal metabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044283 small molecule biosynthetic process
GO:0044708 single-organism behavior
GO:0044723 single-organism carbohydrate metabolic process
GO:0044744 protein targeting to nucleus
GO:0045058 T cell selection
GO:0045064 T-helper 2 cell differentiation
GO:0045073 regulation of chemokine biosynthetic process
GO:0045079 negative regulation of chemokine biosynthetic process
GO:0045124 regulation of bone resorption
GO:0045165 cell fate commitment
GO:0045187 regulation of circadian sleep/wake cycle, sleep
GO:0045188 regulation of circadian sleep/wake cycle, non-REM sleep
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045429 positive regulation of nitric oxide biosynthetic process
GO:0045444 fat cell differentiation
GO:0045453 bone resorption
GO:0045454 cell redox homeostasis
GO:0045580 regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045599 negative regulation of fat cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045624 positive regulation of T-helper cell differentiation
GO:0045628 regulation of T-helper 2 cell differentiation
GO:0045630 positive regulation of T-helper 2 cell differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045721 negative regulation of gluconeogenesis
GO:0045727 positive regulation of translation
GO:0045740 positive regulation of DNA replication
GO:0045765 regulation of angiogenesis
GO:0045778 positive regulation of ossification
GO:0045779 negative regulation of bone resorption
GO:0045785 positive regulation of cell adhesion
GO:0045837 negative regulation of membrane potential
GO:0045861 negative regulation of proteolysis
GO:0045912 negative regulation of carbohydrate metabolic process
GO:0046209 nitric oxide metabolic process
GO:0046364 monosaccharide biosynthetic process
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0046677 response to antibiotic
GO:0046716 muscle cell cellular homeostasis
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046849 bone remodeling
GO:0046850 regulation of bone remodeling
GO:0046851 negative regulation of bone remodeling
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0048305 immunoglobulin secretion
GO:0048511 rhythmic process
GO:0048512 circadian behavior
GO:0048514 blood vessel morphogenesis
GO:0048545 response to steroid hormone
GO:0048634 regulation of muscle organ development
GO:0048635 negative regulation of muscle organ development
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048732 gland development
GO:0048771 tissue remodeling
GO:0048871 multicellular organismal homeostasis
GO:0048872 homeostasis of number of cells
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050714 positive regulation of protein secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050755 chemokine metabolic process
GO:0050769 positive regulation of neurogenesis
GO:0050795 regulation of behavior
GO:0050802 circadian sleep/wake cycle, sleep
GO:0050817 coagulation
GO:0050829 defense response to Gram-negative bacterium
GO:0050830 defense response to Gram-positive bacterium
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051023 regulation of immunoglobulin secretion
GO:0051024 positive regulation of immunoglobulin secretion
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051235 maintenance of location
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051348 negative regulation of transferase activity
GO:0051384 response to glucocorticoid
GO:0051592 response to calcium ion
GO:0051602 response to electrical stimulus
GO:0051607 defense response to virus
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0051962 positive regulation of nervous system development
GO:0051969 regulation of transmission of nerve impulse
GO:0051971 positive regulation of transmission of nerve impulse
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060249 anatomical structure homeostasis
GO:0060326 cell chemotaxis
GO:0060445 branching involved in salivary gland morphogenesis
GO:0060664 epithelial cell proliferation involved in salivary gland morphogenesis
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0061138 morphogenesis of a branching epithelium
GO:0070091 glucagon secretion
GO:0070102 interleukin-6-mediated signaling pathway
GO:0070301 cellular response to hydrogen peroxide
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070498 interleukin-1-mediated signaling pathway
GO:0070555 response to interleukin-1
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070741 response to interleukin-6
GO:0070997 neuron death
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071347 cellular response to interleukin-1
GO:0071354 cellular response to interleukin-6
GO:0071356 cellular response to tumor necrosis factor
GO:0071375 cellular response to peptide hormone stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071384 cellular response to corticosteroid stimulus
GO:0071385 cellular response to glucocorticoid stimulus
GO:0071392 cellular response to estradiol stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071496 cellular response to external stimulus
GO:0071548 response to dexamethasone
GO:0071549 cellular response to dexamethasone stimulus
GO:0071593 lymphocyte aggregation
GO:0071674 mononuclear cell migration
GO:0071838 cell proliferation in bone marrow
GO:0071863 regulation of cell proliferation in bone marrow
GO:0071864 positive regulation of cell proliferation in bone marrow
GO:0071887 leukocyte apoptotic process
GO:0072538 T-helper 17 type immune response
GO:0072539 T-helper 17 cell differentiation
GO:0072540 T-helper 17 cell lineage commitment
GO:0072593 reactive oxygen species metabolic process
GO:0090316 positive regulation of intracellular protein transport
GO:0097050 type B pancreatic cell apoptotic process
GO:0097529 myeloid leukocyte migration
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901342 regulation of vasculature development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902593 single-organism nuclear import
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903428 positive regulation of reactive oxygen species biosynthetic process
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1903533 regulation of protein targeting
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1903829 positive regulation of cellular protein localization
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904037 positive regulation of epithelial cell apoptotic process
GO:1904407 positive regulation of nitric oxide metabolic process
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:1990637 response to prolactin
GO:1990646 cellular response to prolactin
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2000117 negative regulation of cysteine-type endopeptidase activity
GO:2000147 positive regulation of cell motility
GO:2000364 regulation of STAT protein import into nucleus
GO:2000366 positive regulation of STAT protein import into nucleus
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000379 positive regulation of reactive oxygen species metabolic process
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
GO:2000551 regulation of T-helper 2 cell cytokine production
GO:2000553 positive regulation of T-helper 2 cell cytokine production
GO:2000659 regulation of interleukin-1-mediated signaling pathway
GO:2000660 negative regulation of interleukin-1-mediated signaling pathway
GO:2000674 regulation of type B pancreatic cell apoptotic process
GO:2000676 positive regulation of type B pancreatic cell apoptotic process
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005138 interleukin-6 receptor binding
GO:0008083 growth factor activity
GO:0070851 growth factor receptor binding
Cellular Component GO:0005896 interleukin-6 receptor complex
GO:0009897 external side of plasma membrane
GO:0043235 receptor complex
GO:0098552 side of membrane
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04630 Jak-STAT signaling pathway
hsa04640 Hematopoietic cell lineage
hsa04668 TNF signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-1059683: Interleukin-6 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-112411: MAPK1 (ERK2) activation
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-110056: MAPK3 (ERK1) activation
R-HSA-112409: RAF-independent MAPK1/3 activation
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28166197Hepatocellular CarcinomaInhibit immunity (T cell function)Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation.
27001312GliomaInhibit immunity (T cell function)Mechanistically, glioma initiating CD133(+) cells and Mφs/microglia cointeraction activated expression of B7-H4 via IL6 and IL10 in both tumor cells and microenvironment supporting cells. IL6-activated STAT3 bound to the promoter of B7-H4 gene and enhanced B7-H4 expression. Furthermore, CD133(+) cells mediated immunosuppression through B7-H4 expression on Mφs/microglia by silencing of B7-H4 expression on these cells, which led to increased microenvironment T-cell function and tumor regression in the xenograft glioma mouse model.
26334519MelanomaInhibit immunity (T cell function)In the tumor microenvironment, the combination therapy led to significantly downregulated levels of immunosuppressive factors, such as decreased numbers of myeloid-derived suppressor cells and regulatory T cells (Treg) cells and declined levels of interleukin-6 and chemokine ligand 2-in correlation with increased levels of proinflammatory cytokines, including tumor necrosis factor-α and IFN-γ as well as an elevation in the CD8(+) T-cell population.
26216383Ovarian CarcinomaInhibit immunityInterleukin-6 is associated with chemoresistance and an immune-suppressive tumor microenvironment. Functional IL-6R blocking is feasible and safe in EOC patients treated with carboplatin/(pegylated liposomal)doxorubicin, using 8 mg/kg tocilizumab.
25363661GlioblastomaInhibit immunityWhile a number of key immunosuppressive cytokines were overexpressed in the treated cells, including IL-10, IL-6 and GM-CSF, suppression could be alleviated in a number of treated GBM lines by inhibition of prostaglandin E2.
22710190Gastric CarcinomaPromote immunity (T cell function)CD8(+) T cells that produce interleukin (IL)-17 (Tc17 cells) promote inflammation and have been identified in tumors. Tumor-activated monocytes secreted IL-6, IL-1β, and IL-23, which promoted development of Tc17 cell populations.
22653638MelanomaInhibit immunityHigh amounts of IL-6, a key cytokine of immunosuppres-sion and decreased quality of life in tumor-bearing hosts. To block IL-6-signaling in vivo, tumor-bearing mice wereadministered with anti-IL-6R mAb. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
22588558Nasopharyngeal CarcinomaInhibit immunityIn epithelial cells, LMP1 up-regulated HLA class I APM. This effect could be counteracted by c-Myc, which itself was up-regulated by LMP1 apparently through IL6 induction and Jak3/STAT3 activation. These findings raise the possibility that c-Myc activation in nasopharyngeal carcinoma (NPC) might antagonise the effect of LMP1 on HLA class I expression thus contributing to immune escape of tumour cells.
24651526Colon carcinomaImmunotherapy targetEmbelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling. In addition to inhibiting proliferation of tumor epithelial cells, embelin suppressed colonic IL-6 expression and secretion, and subsequently STAT3 activation in vivo.
16397267Pancreatic carcinomaPromote immunity (T cell function)C57BL/6 EL-TGF-alpha x Trp53-/- mice, which develop spontaneous ductal pancreatic carcinoma, were generated. Intratumoral cytokine secretion of tumor necrosis factor-alpha, IFN-gamma, IL-6, and MCP-1 was lower in spontaneous tumors as well as the number of adoptively transferred tumor-specific T cells.
27407095Cervical carcinomaPromote immunityIntravaginal treatment of IL7-Fc, but not native IL7, induces upregulation of chemokines (CXCL10, CCL3, CCL4, and CCL5), cytokines (IFNγ, TNFα, IL6, and IL1β), and an adhesion molecule (VCAM-1) in the genital tract, leading to the recruitment of several leukocytes, including CD4, CD8, γδ T cells, and dendritic cells.
28533357Prostate CarcinomaInhibit immunityTLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. The PMN-MDSCs from tetracycline-treated RM9-Tlr9ONtumors increased the immunosuppressive activity of the STAT3 transcription factor, thereby more potently inhibiting T cell proliferation. We identified LIF, an IL-6-type cytokine and STAT3 activator, as a potential mediator of crosstalk between TLR9-expressing prostate cancer cells and PMN-MDSCs.
23514705Pancreatic CarcinomaInhibit immunity (T cell function)Luminex analysis indicated that PSC but not human fetal primary pancreatic fibroblast cells (HPF; negative controls) produced MDSC-promoting cytokines [interleukin (IL-6), VEGF, macrophage colony-stimulating factor (M-CSF) ] and chemokines (SDF-1, MCP-1).
19494278Colon Carcinoma; Prostate CarcinomaInhibit immunityPGDH-mediated antitumor effect was associated with attenuated tumor-induced immune suppression and substantially reduced secretion of immunosuppressive mediators and cytokines such as PGE(2), IL-10, IL-13, and IL-6 by intratumoral CD11b cells. We show also that introduction of 15-PGDH gene in tumor tissue is sufficient to redirect the differentiation of intratumoral CD11b cells from immunosuppressive M2-oriented F4/80(+) tumor-associated macrophages (TAM) into M1-oriented CD11c(+) MHC class II-positive myeloid APCs.
29034589Colon CarcinomaInhibit immunity (T cell function)Giving angiotensin II receptor blockers (ARB) to C57BL/6 mice bearing murine colon cancer cell line MC38 resulted in significant enhancement of tumor antigen gp70 specific T cells. ARB administration did not change the numbers of CD11b+ myeloid cells in tumors, but significantly reduced their T-cell inhibitory ability along with decreased production of various immunosuppressive factors including interleukin (IL)-6, IL-10, vascular endothelial growth factor (VEGF), and arginase by CD11b+ cells in tumors.
27593937Hepatocellular CarcinomaInhibit immunity (T cell function); immunotherapy targetTumor-associated fibroblasts (TAFs) attracted monocytes by the stromal cell-derived factor (SDF)-1a/CXCR4 pathway and induced their differentiation into MDSCs through interleukin (IL)-6-mediated STAT3 activation. Together, our results are the first to show that TAF-derived cytokines, such as IL-6 and SDF-1a, can induce MDSC generation and activation and then impair human anti-tumor immune responses, which create favorable conditions for HCC progression. Consequently, methods in which immunotherapy is combined with IL-6, SDF-1a or STAT3 inhibition may offer an improved option to eliminate suppressive CD11b+ myeloid cells in HCC patients.
24777249SacromaInhibit immunity (T cell function)Here, we showed that in tumor-bearing mice, generation of tumor antigen-specific effector T-helper cells (TH1) was significantly attenuated, and impaired TH1 differentiation was restored by the temporal blockade of interleukin (IL)-6 activity at the T-cell priming phase. Despite comparable suppressive activity of IL-6(+/+) and IL-6(-/-) MDSC on primary T-cell activation, transfer of IL-6(+/+) MDSC, but not IL-6(-/-) MDSC, dampened the efficient induction of effector TH1 cells and counteracted CD4(+) T cell-mediated antitumor immunity including cognate help for CD8(+) T cells in vivo.
20805420Pancreatic Ductal AdenocarcinomaPromote immunity (T cell function)Mice bearing IL-6 Pan02 tumors demonstrated significant delay in tumor growth and better overall median survival compared with mice bearing WT or EV Pan02 tumors. Immunohistochemical analysis demonstrated an increase in Th17 cells (CD4(+)IL-23R(+) cells and CD4(+)IL-17(+) cells) in tumors of the IL-6 Pan02 group compared with WT or EV Pan02 tumors. Thus, the addition of IL-6 to the tumor microenvironment skews the balance toward Th17 cells in a murine model of pancreatic cancer.
19022917Colorectal CarcinomaInhibit immunity (T cell function)Moreover, T8reg were able to suppress CD4(+)CD25(-) T cell proliferation and Th1 cytokine production ex vivo, demonstrating that tumour-infiltrating T8reg have strong suppressive capacities. T8reg numbers correlated with the tumour stage and with micro-invasive status. Finally, interleukin 6 and TGF beta 1 synergistically induced the generation of CD8(+)CD25(+)Foxp3(+) T cells ex vivo.
29486738Breast Carcinoma; MelanomaInhibit immunity (T cell function)IL-6, IL-8 and XIAP showed increased expressions in PTX-treated cells and this over-production effect was inhibited in TLR4-transient knockdown cells. Apoptotic cells were detected higher when PTX and CpdA were combined than PTX treatment alone. Isobologram exhibited the synergistic effect of CpdA and PTX. CpdA could significantly decrease expressions of IL-6, XIAP and IL-8, as well as excreted IL-8 levels together with reduced cancer viability after PTX treatment. The acquired TLR4-mediated PTX resistance in BCA and melanoma is explained partly by the paracrine effect of IL-6 and IL-8 released into the tumor microenvironment and over-production of anti-apoptotic protein, XIAP, in BCA cells and importantly CpdA could reduce this effect and sensitize PTX-induced apoptosis in a synergistic manner.
17942936Breast CarcinomaInhibit immunity (T cell function)We have tested this hypothesis using the 4T1 mammary carcinoma and IL-1 receptor (IL-1R)-deficient mice which have a reduced potential for inflammation, and IL-1R antagonist-deficient mice, which have an increased potential for inflammation. Consistent with our hypothesis, IL-1R-deficient mice have a delayed accumulation of MDSC and reduced primary and metastatic tumor progression.Accumulation of MDSC and tumor progression are partially restored by IL-6, indicating that IL-6 is a downstream mediator of the IL-1beta-induced expansion of MDSC.
17848619Ovarian CarcinomaInhibit immunity (T cell function)Ovarian cancer ascites contained high concentrations of LIF and IL-6. Recombinant LIF and IL-6 skew monocyte differentiation into TAM-like cells by enabling monocytes to consume monocyte-colony-stimulating factor (M-CSF). Depletion of LIF, IL-6, and M-CSF in ovarian cancer ascites suppressed TAM-like cell induction.
24990079melanomaPromote immunity (T cell function); increase the efficacy of immunotherapyThe HspX protein induces DC maturation and proinflammatory cytokine production (TNF-α, IL-1β, IL-6, and IFN-β) through TLR4 binding partially mediated by both the MyD88 and the TRIF signaling pathways.
24970861Cervical CarcinomaInhibit immunityWe show evidence of constitutive activation of the IL-6/STAT3 signaling pathway in the tumor, including TAMs, and in APCs in the spleen.
24947042melanoma, lung carcinomaPromote immunityMechanistic investigations revealed a defective induction of the γδT17 cell response in lungs of Abt mice; here, more aggressive tumor development was observed, possibly related to a reduction in IL6 and IL23 expression there.
24912675Hepatocellular CarcinomaInhibit immunityWe found that interleukin-6 (IL-6) was differentially expressed in hepatocytes depending on cancerous malignancy and TM4SF5 expression.
24894091MelanomaInhibit immunityImmunohistochemical data of infiltrating (suppressive) cells, such as T cells, regulatory T cells, myeloid-derived suppressor cells, and mast cells, or the expression of T-cell inhibitory factors (PD-1/PD-L1, IDO, and galectins), cytotoxic molecules (granzyme-B), melanocyte differentiation antigens, HLA class-I and tolerogenic cytokines [interleukin (IL)-1, IL-6, IL-10, TNF-α, and TGF-β] were correlated statistically to clinical outcome and overall survival (OS).
29642948melanomaPromote immunity (infiltration)Among the immune-profile biomarkers analyzed, only interleukin-6 was associated with the risk of toxicity.
29632307plasma cell myelomaPromote immunityThis impairment could be attributed to autocrine secretion of IL6 by MM-monocytes and activation of their P38 MAPK pathway.
27879265Breast CarcinomaInhibit immunityIL6 is a pleiotropic cytokine with both pro- and anti-inflammatory properties, which acts directly on cancer cells to promote their survival and proliferation. How IL6 modulates the host immune response in cancer patients is unclear. Here, we show the IL6 signaling response in peripheral blood T cells is impaired in breast cancer patients and is associated with blunted Th17 differentiation. The mechanism identified involved downregulation of gp130 and IL6Rα in breast cancer patients and was independent of plasma IL6 levels.
27829137Colorectal Cancinoma; Pancreatic Ductal AdenocarcinomaInhibit immunity; resistant to immunotherapyHere, we describe tumor-induced alterations of the host metabolic response to caloric deficiency that cause intratumoral immune suppression. In pre-cachectic mice with transplanted colorectal cancer or autochthonous pancreatic ductal adenocarcinoma (PDA), we find that IL-6 reduces the hepatic ketogenic potential through suppression of PPARalpha, the transcriptional master regulator of ketogenesis. Therefore, tumor-induced IL-6 impairs the ketogenic response to reduced caloric intake, resulting in a systemic metabolic stress response that blocks anti-cancer immunotherapy.
27797936Pancreatic Ductal AdenocarcinomaInhibit immunity; decrease the efficacy of immunotherapyLimited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy. These preclinical results indicate that targeted inhibition of IL-6 may enhance the efficacy of anti-PD-L1 in PDAC.
21480223Bladder CarcinomaInhibit immunityBoth myeloid cell subsets from cancer patients were highly activated and produced substantial amounts of proinflammatory chemokines/cytokines including CCL2, CCL3, CCL4, G-CSF, IL-8 and IL-6. We demonstrate that these highly activated inflammatory myeloid cells represent a source of multiple chemokines/cytokines and may contribute to inflammation and immune dysfunction in bladder cancer.
29308316Pancreatic Ductal AdenocarcinomaImmunotherapy targetTargeting of mesenchymal pancreatic tumors in vivo with anti-IL-6RmAb (RoActemra) successfully decreased tumor growth in immunodeficient mice, inhibited the inflammatory stroma and NF-kB-p65 and STAT3 phosphorylation in cancer cells.
24231354OsteosarcomaPromote immunityIn vivo, IL-6 was required for IR-induced senescence, which elicited NKT cell infiltration and a host inflammatory response. Mice lacking IL-6 or NKT cells had accelerated development of IR-induced osteosarcomas.
22822050Lung CarcinomaInhibit immunityBiologically, this resulted in a consequential impairment of protumorigenic myeloid-derived suppressor cells (MDSC), as restoration of IL-6 recovered both MDSC suppressor function and metastasis susceptibility in Ido1-nullizygous mice.
22020332Skin PapillomaPromote immunityDecreased tumor outgrowth is accompanied by increased expression of the proinflammatory cytokines interleukin (IL)-1β and IL-6 by the lymph node (LN) dendritic cells.
20386569Breast CarcinomaInhibit immunityIL-6 acts in an autocrine fashion to skew RAW264.7 macrophage cell differentiation into M2d macrophages.
29713085Chronic Lymphocytic LeukemiaEssential for immunotherapyTranscriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. IL-6/STAT3 blockade diminished CAR T cell proliferation.
25238096lung carcinoma; melanoma; colon carcinomaInhibit immunity (T cell function)Chop-deficient MDSCs displayed reduced signaling through CCAAT/enhancer-binding protein-beta, leading to a decreased production of interleukin-6 (IL-6) and low expression of phospho-STAT3. IL-6 overexpression restored immune-suppressive activity of Chop-deficient MDSCs.
25170116breast carcinoma; colon carcinomaInhibit immunityMDSC and tumor cell cross-talk enhances IL-6 production while IL-16 enhances tumor progression, MDSC suppression and suppressive activity
23269246Pancreatic ductal adenocarcinomaInhibit immunityTo study the role of RAGE expression in the setting of mutant Ras-promoted pancreatic carcinogenesis (KC), a triple-transgenic model of spontaneous murine PDA in a RAGE-null background (KCR) was generated. KCR mice also maintained a significantly less suppressive milieu evidenced by marked decreases in CCL22 in relation to CXCL10 and diminished serum levels of IL-6.
21969559MelanomaInhibit immunityIndeed, upon manipulation of the melanoma microenvironment with the phosphodiesterase-5 inhibitor sildenafil, we observed reduced levels of numerous inflammatory mediators (e.g., IL-1β, IL-6, VEGF, S100A9) in association with decreased MDSC amounts and immunosuppressive function, indicating an antiinflammatory effect of sildenafil
21926464MelanomaPromote immunity (infiltration)Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. Mechanistically, IL-6 produced by nonhematopoietic stromal cells acted cooperatively with soluble IL-6 receptor-α and thermally induced gp130 to promote E/P-selectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.
21784871Breast CarcinomaInhibit immunityFurthermore, we showed that treatment with these NPs resulted in priming of the immune TME, characterized by increased IFN-gamma, p-STAT-1, GM-CSF, IL-2, IL-15, and IL-12b and reduced TGF-beta, IL-6, and IL-10 protein expression. In addition, we found significantly increased tumor infiltration by activated CD8(+) T cells, M1 macrophages, and dendritic cells.
16982774MelanomaInhibit immunityCD14+ monocytes isolated from healthy donors and differentiated with interleukin (IL)-4 and granulocyte macrophage colony-stimulating factor in the presence of tumor-derived microvesicles turned into HLA-DR(-/low) cells, retaining CD14 expression and failing to up-regulate costimulatory molecules, such as CD80 and CD86.These phenotypic changes were paralleled by a significant release of different cytokines, including IL-6, tumor necrosis factor-alpha, and transforming growth factor-beta (TGF-beta), and a dose-dependent suppressive activity on activated T-cell-proliferation and cytolytic functions, which could be reversed by anti-TGF-beta-neutralizing antibodies.
16917008Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Inhibit immunityThese abnormalities may be attributed to elevated production of autocrine cytokines such as IL-6, activated p38 and STAT3, and inhibited MEK/ERK signaling pathways in the progenitor cells. Treatment with neutralizing IL-6-specific antibody and, more importantly, p38 inhibitor, or both, could correct these abnormalities. Treating patient-derived cells with these agents not only significantly increased cell yield but also produced MoDCs that were as functional as their normal counterparts.
16801397MelanomaInhibit immunityHere, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAF(V600E)). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1720.802
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0970.94
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2130.824
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.50.0549
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7420.287
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1840.592
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1390.822
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1390.876
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6270.509
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.5640.263
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8410.634
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4240.196
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL6
Nameinterleukin 6
Aliases IL-6; BSF2; HSF; interferon, beta 2; IFNB2; interleukin 6 (interferon, beta 2); B-cell differentiation facto ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL6 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IL6.
ID Name Drug Type Targets #Targets
DB01404GinsengSmall MoleculeAHR, IL6, PTGS23
DB05017YSIL6Small MoleculeIL6, TNF2
DB05470VX-702Small MoleculeIL1B, IL6, MAPK14, TNF4
DB05513AtiprimodSmall MoleculeIL6, TNF2
DB05744CRx-139Small MoleculeCRP, IL10, IL6, TNF4
DB05767AndrographolideSmall MoleculeIL1B, IL6, NFKB1, NFKB2, TNF5
DB06083TapinarofSmall MoleculeCXCL8, IL12B, IL2, IL64
DB09036SiltuximabBiotechIL61
DB09221PolaprezincSmall MoleculeFLT1, HSP90AA1, HSP90AB1, IL3, IL6, NGF, PDGFRB, TNF8
DB11967BinimetinibSmall MoleculeIL1B, IL6, TNF3
DB12140DilmapimodSmall MoleculeIL1B, IL6, TNF3